Stage IIIA Skin Melanoma Recruiting Phase 1 Trials for Romidepsin (DB06176)

IndicationStatusPhase
DBCOND0029533 (Stage IIIA Skin Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01638533Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionTreatment